

22368 U.S. PTO  
10/664506  
09/17/03

-Practitioner's Docket No. : MPI100-079P1RCP2CN1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of  
Inventor(s): Rachel E. Meyers, et al.

For: 21481, A NOVEL DEHYDROGENASE MOLECULE AND USES THEREFOR

1. Type of Application

This new application is for a(n)

- Original (nonprovisional)  
 Design  
 Plant  
 Divisional.  
 Continuation.  
 Continuation-in-part (C-I-P).

---

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- deposited with the United States Postal Service in an envelope addressed to the Mail Stop Patent Application.  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.10\*

- with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"  
Mailing Label No. EL992152684US

TRANSMISSION

- transmitted by facsimile to the Patent and Trademark Office.

  
Signature  
Sean Hunziker  
(type or print name of person certifying)

Date: September 17, 2003

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).  
"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. : MPI00-079P1RCP2CN1M**

**2. Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)**

- The new application being transmitted claims the benefit of prior U.S Application Serial No. 09/838,561 filed April 18, 2001, which is a continuation-in-part of U.S. Application Serial No. 09/816,760 filed March 23, 2001, which is a continuation-in-part of U.S. Application Serial No. 09/634,955 filed August 8, 2000, which claims benefit of U.S. Provisional Application Serial No. 60/192,002 filed March 24, 2000.

**3. Maintenance of Copendency of Prior Application**

- A.  Extension of time in prior application  
B.  Conditional Petition for Extension of Time in Prior Application  
*(complete this item, if previous item not applicable)*  
 A conditional petition for extension of time is being filed in the pending **prior** application.  
 A copy of the conditional petition filed in the prior application is attached.

**4. Abandonment of Prior Application (*if applicable*)**

- Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

**Notification in Parent Application of This Filing**

- A notification of this continuation is being filed in the parent application from which this application claims priority under 35 U.S.C. Section 120.

**5. Papers Enclosed**

**Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application**

103 Pages of Specification, including  
96 Pages of Description  
6 Pages of Claims  
1 Page of Abstract  
43 Sheet of Drawings (Figure(s) 1A-33)

- The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. Section 1.84(b).  
 Formal  
 Informal

**Practitioner's Docket No. : MPI00-079P1RCP2CN1M**

**6. Additional Papers Enclosed**

- Information Disclosure Statement (37 C.F.R. Section 1.98)(2 pages)  
 Form PTO-1449 (PTO/SB/08A and 08B)(17 pages)  
 Citations  
 Declaration of Biological Deposit  
 30 pages of paper copy of Sequence Listing (37 CFR Section 1.821-1.823) and 4 pages of Submission of "Sequence Listing," Computer Readable Copy, and/or Amendment Pertaining Thereto for Biotechnology Invention Containing Nucleotide and/or Amino Acid Sequence (37 CFR Section 1.821(f))  
 Authorization of Attorney(s) to Accept and Follow Instructions from Representative  
 Special Comments  
 Other:

**7. Declaration or Oath (including power of attorney)**

- (35 pages) Copy of the executed Declaration and Power of Attorney document filed in prior U.S. Application Serial No. 09/838,561, filed April 18, 2001.  
 Not Enclosed.

**8. Assignment**

- (18 pages) Copy of the Assignment of the invention to Millennium Pharmaceuticals, Inc., filed in prior U.S. Application Serial No. 09/838,561, filed April 18, 2001, a copy of which
- is enclosed.  
 will follow.

**Practitioner's Docket No. : MPI00-079P1RCP2CN1M**

**9. Fee Calculation (37 C.F.R. Section 1.16)**

**A.  Regular application**

CLAIMS AS FILED					
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a) \$750.00
Total Claims (37 C.F.R. Section 1.16(c))	42	- 20 =	22	\$18.00	\$396.00
Independent Claims (37 C.F.R. Section 1.16(b))	8	- 3 =	5	\$84.00	\$420.00
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))	0	\$280.00			\$0.00

**Filing Fee Calculation                                    \$1,566.00**

- Amendment canceling extra claims is enclosed.
- Amendment deleting multiple-dependencies is enclosed.
- Fee for extra claims is not being paid at this time.

**Practitioner's Docket No. : MPI00-079P1RCP2CN1M**

**10. Method of Payment & Fees**

- Check in the amount of \$ \_\_\_\_\_.  
 Charge Account No. 501668 in the amount of \$1,566.00  
A duplicate of this transmittal is attached.

**11. Authorization to Charge Additional Fees**

- The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 501668.
- 37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)  
 37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims)  
 37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)  
 37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to Section 1.136(a)).  
 37 C.F.R. Section 1.17 (application processing fees)  
 37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. Section 1.311(b))

**12. Instructions as to Overpayment**

- Credit Account No. 501668.  
 Refund

**13. Correspondence Address**

Direct all future correspondence to:

Customer Number 30405  
OR  
Intellectual Property Department  
MILLENNIUM PHARMACEUTICALS, INC.  
75 Sidney Street  
Cambridge, MA 02139

September 17, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By Kerri Pollard Schray

Kerri Pollard Schray  
Registration No. 47,066  
75 Sidney Street  
Cambridge, MA 02139  
Telephone – (617) 551-3676  
Facsimile – (617) 551-8820

Statement Where No Further Pages Added

This transmittal ends with this page.